The Supreme Court is reviewing the SEC's disgorgement power, a key enforcement tool, debating whether the agency must prove specific economic harm to victims, with most justices appearing skeptical of imposing such a requirement.
Justice Gorsuch raised concerns about defendants' Seventh Amendment right to a jury trial in SEC cases where disgorged funds are not returned to victims, linking the issue to the recent Jarkesy precedent.
A federal judge issued a broad injunction blocking the Department of Health and Human Services (HHS) from withholding funds for gender-affirming care, ruling the action was an unlawful overreach of executive authority.
The legal battles highlight ongoing tensions between executive agency power, congressional statutes, and judicial review in both financial regulation and healthcare policy, with significant implications for regulated industries.
12 quotes
Concerns Raised
Potential for the Supreme Court to curtail SEC disgorgement powers, making it harder to prosecute complex financial fraud.
The 'chilling effect' of executive branch threats on healthcare providers, which may persist even after favorable court rulings.
A growing trend of applying jury trial rights to administrative enforcement, potentially complicating and slowing regulatory actions.
Executive overreach in using federal funding to dictate healthcare policy without proper rulemaking.
Opportunities Identified
Supreme Court clarity on the scope of SEC disgorgement could solidify the agency's enforcement framework.
Judicial rulings that reinforce the Administrative Procedure Act can provide stability for businesses against arbitrary executive actions.